查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870612

肺氣腫治療市場依治療方法、藥物類別、治療線、給藥途徑、劑型、通路及產品類型分類－2025年至2032年全球預測

Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route Of Administration, Dosage Form, Distribution Channel, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺氣腫治療市場將成長至 119.4 億美元，複合年成長率為 7.22%。

關鍵市場統計數據
基準年 2024 68.3億美元
預計年份：2025年 73.2億美元
預測年份 2032 119.4億美元
複合年成長率 (%) 7.22%

全面介紹不斷變化的肺氣腫治療格局、臨床重點以及影響治療決策的新挑戰

由於肺氣腫的病理進行性、症狀負擔沉重且醫療資源利用率高，因此它仍然是慢性呼吸系統疾病管理中臨床和商業性的重點關注領域。治療方案包括藥物治療和手術治療，兩者各有其獨特的臨床目標。藥物治療旨在控制發炎、緩解氣流阻塞和減輕病情加重，而手術治療則適用於經過嚴格篩選的患者，以改善肺力學和生活品質。本導言概述了正在重塑患者照護、創新研發和支付方格局的各種因素。

藥物、器械輸送和手術技術的創新如何重塑肺氣腫治療路徑和相關人員的期望

肺氣腫的治療格局正在經歷變革性變化，這主要得益於藥物治療的創新、外科技術的改進以及對綜合護理模式的日益重視。新型藥物組合和醫療設備平台正在擴展臨床選擇，而微創手術和瓣膜療法則為過去選擇有限的患者提供了新的希望。這些變化並非孤立發生，而是與監管決策、報銷途徑和更新的臨床指南相互作用，加速了某些治療方法的推廣應用。

2025年美國關稅調整對肺氣腫護理供應鏈、採購韌性和臨床連續性的營運和策略影響

2025年美國實施的關稅和貿易政策變化所帶來的累積影響，為醫療保健製造商和經銷商創造了一個敏感的經營環境。關稅變化影響了專用吸入裝置、某些生物製藥成分以及用於高級肺部護理的外科設備的進口成本。製造商透過重新評估其供應鏈、重新談判採購合約以及加快關鍵零件的本地化生產來應對這一挑戰，以降低貿易相關成本波動帶來的風險。

對影響臨床應用和商業性定位的治療類型、藥物類別、治療線和供應管道進行多方面細分分析

關鍵的細分分析揭示了治療方案和商業性路徑如何因治療方法類型、藥物類別、治療線、給藥途徑、劑型、分銷管道和產品類型而異。根據治療類型，市場可分為藥物治療（例如抗生素、支氣管擴張劑、皮質類固醇和祛痰藥）和外科手術，後者包括肺泡切除術、肺移植術、肺部減容手術和瓣膜治療。這種二分性凸顯了建立協調的治療路徑的必要性，該路徑應整合藥物最佳化和手術選擇標準。

美洲、歐洲、中東和非洲以及亞太地區在監管、報銷和醫療服務方面的區域差異會影響醫療服務的可近性和商業化策略。

區域趨勢正深刻影響著美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、法規結構和商業策略。在美洲，對整合式醫療體系和以價值為導向的醫療模式的重視，使得那些已被證實能顯著降低住院率並改善患者長期預後的治療方法和干涉措施成為優先考慮的因素，這促使支付方和醫療服務提供方仔細審查療效比較和總醫療成本。這種環境推動了人們對持續維持治療創新以及支持病患依從性的醫療設備的興趣。

致力於推動醫療、器材和手術解決方案以滿足多方面肺氣腫治療需求的公司面臨的競爭格局和策略挑戰

肺氣腫治療領域的競爭格局由成熟的製藥公司、專業的醫療設備製造商以及正在開發新型治療方法的生物技術公司共同塑造。現有企業憑藉其豐富的呼吸系統治療產品組合、深厚的臨床醫生關係以及完善的分銷網路，維持著在醫院和零售管道的供應。同時，新興企業則專注於差異化的作用機制、標靶的醫療設備-藥物組合或手術創新，從而開闢臨床和商業性的利基市場。對於那些希望將臨床專業知識與醫療設備工程相結合，或透過合作開發加速市場准入的公司而言，策略聯盟和許可協議仍然至關重要。

為產業領導者提供切實可行的策略建議，以協調臨床證據、器材創新、供應鏈韌性和區域市場進入的實施。

產業領導者應提出切實可行的建議，以平衡臨床差異化、商業性現實和營運韌性。首先，應優先考慮整合證據，將隨機對照試驗數據與真實世界結果相結合，重點關注諸如減少病情加重、避免住院和提高生活品質等指標，以滿足支付方和指南的要求。將這些臨床數據轉化為清晰的價值提案，既要考慮短期資源影響，又要兼顧長期健康效益。

研究結果透過以證據為導向的調查方法檢驗，該方法結合了系統性文獻綜述、對臨床醫生和管理人員的訪談以及供應鏈政策分析。

本分析的調查方法結合了嚴謹的二手資料分析和有針對性的質性研究，以確保提供全面、實證的觀點。對同儕審查的臨床文獻、監管指南和公共衛生指令的系統性回顧，提供了基礎的臨床和科學背景。此外，對醫療設備認證、手術相關文獻和技術評估報告的評估，也反映了藥物和外科領域的進展。

關鍵整合凸顯了臨床創新、營運韌性和在地化市場策略對肺氣腫治療成功的重要性。

總之，肺氣腫治療領域正處於一個轉折點，藥物改良、劑量創新和技術進步與不斷變化的支付方期望和區域差異交織在一起。臨床決策越來越以對患者和醫療系統至關重要的結果為導向，相關人員也透過強調永續的維持治療、透過更先進的設備提高患者依從性以及精準的手術選擇來應對這一變化。這些趨勢為兼顧臨床療效、擴充性和經濟合理性的差異化治療策略創造了機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 為肺氣腫患者推出配備智慧監測功能的個人化吸入器裝置
  • 引入再生醫學幹細胞療法，以修復肺泡組織，用於治療肺氣腫
  • 推出新一代長效支氣管擴張劑組合藥物，安全性更高。
  • 透過雲端連接的肺功能儀與數位健康平台整合進行遠端肺氣腫監測
  • 開發靶向抗炎生物製藥以減少肺氣腫中的慢性肺泡破壞
  • 生技Start-Ups與肺部研究中心合作，加速肺氣腫藥物的核准

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺氣腫治療市場（依治療方式分類）

  • 藥物治療
    • 抗生素
    • 支氣管擴張劑
    • 皮質類固醇
    • 祛痰藥
  • 手術治療
    • 切除術
    • 肺移植
    • 肺減容手術
    • 瓣膜治療

9. 按藥物類別分類的肺氣腫治療市場

  • 抗膽鹼能藥物
  • BETA-激動劑
  • 組合藥物

第10章 按治療線分類的肺氣腫治療市場

  • 輔助性治療
  • 一線治療
  • 維持治療
    • 聯合治療
    • 長效抗膽鹼能藥物
    • 長效BETA2受體激動劑
  • 救援
    • 短效抗膽鹼能藥物
    • 短效BETA2受體激動劑

第11章 肺氣腫治療市場（依給藥途徑分類）

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
    • 緩霧吸入器
  • 靜脈注射
    • 靜脈注射
    • 注射
  • 口服
    • 膠囊
    • 解決方案
    • 藥片

第12章 肺氣腫治療市場依劑型分類

  • 膠囊
  • 吸入器
  • 噴霧器
  • 解決方案
  • 藥片

第13章 肺氣腫治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 依產品類型分類的肺氣腫治療市場

  • 品牌
  • 學名藥

第15章 各地區肺氣腫治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 肺氣腫治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國肺氣腫治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc.
    • Chiesi Farmaceutici SpA
    • Sunovion Pharmaceuticals Inc.
    • Sandoz International GmbH
    • Cipla Limited
Product Code: MRR-1A1A064C021A

The Emphysema Treatment Market is projected to grow by USD 11.94 billion at a CAGR of 7.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.83 billion
Estimated Year [2025] USD 7.32 billion
Forecast Year [2032] USD 11.94 billion
CAGR (%) 7.22%

A comprehensive introduction outlining the evolving emphysema treatment environment, clinical priorities, and emerging pressures shaping therapeutic decision-making

Emphysema remains a clinical and commercial priority within chronic respiratory disease management, driven by its progressive pathology, symptomatic burden, and high healthcare utilization. The therapeutic landscape comprises both pharmacological and surgical approaches, each carrying distinct clinical objectives: pharmacological strategies aim to control inflammation, relieve airflow obstruction, and reduce exacerbations, while surgical options are reserved for carefully selected patients to improve lung mechanics and quality of life. This introduction frames the converging forces reshaping patient care, innovation pipelines, and the payer environment.

Over recent years, clinical practice has shifted toward personalized treatment pathways that integrate long-acting bronchodilators, targeted anti-inflammatory regimens, and precision selection for surgical intervention. Advances in device technology and procedural techniques have refined therapeutic delivery, improving tolerability and adherence. At the same time, health systems are emphasizing value-based outcomes, prompting stakeholders to reevaluate treatment appropriateness, long-term management strategies, and interventions that meaningfully reduce hospital admissions.

Given these dynamics, industry participants-spanning drug developers, device manufacturers, payers, and provider networks-must reconcile clinical evidence with operational realities to design scalable solutions. This introduction sets the stage for a deeper exploration of how shifting scientific, regulatory, and economic pressures create both constraints and opportunities across the continuum of emphysema care.

How innovations in pharmacotherapy, device delivery, and procedural techniques are reshaping emphysema care pathways and stakeholder expectations

The landscape of emphysema treatment is undergoing transformative shifts driven by innovation in pharmacotherapy, refinement of surgical techniques, and a growing emphasis on integrated care models. Novel drug combinations and device platforms are expanding clinical options, while minimally invasive procedures and valve therapies provide alternatives for patients who historically had limited choices. These changes are not isolated; they interact with regulatory decisions, reimbursement pathways, and clinical guideline updates to accelerate adoption curves for certain interventions.

Concurrently, the shift toward patient-centered care has elevated metrics such as quality of life, exercise tolerance, and exacerbation reduction over simple physiological markers. This reorientation compels developers to demonstrate real-world effectiveness and durability of benefit. Advances in inhalation technologies, including dry powder and soft mist inhalers, are increasing the precision and convenience of drug delivery, thereby improving adherence and therapeutic effect. On the surgical side, refinements in lung volume reduction surgery and bronchoscopic valve therapy are generating new evidence for subgroup benefit, prompting multidisciplinary teams to reevaluate candidacy criteria.

These transformative shifts are amplified by digital health integration, remote monitoring, and telemedicine-enabled follow-up, which collectively support early intervention and tailored maintenance strategies. As stakeholders respond, the market is recalibrating toward interventions that can provide measurable patient benefit while aligning with payer expectations for cost-effectiveness and demonstrable outcomes.

Operational and strategic consequences of United States tariff realignments in 2025 on supply chains, procurement resilience, and clinical continuity for emphysema therapies

The cumulative impact of tariff and trade policy changes in the United States in 2025 created an operational context that healthcare manufacturers and distributors had to navigate carefully. Shifts in tariff schedules affected the importation costs of specialized inhalation devices, certain biopharmaceutical components, and surgical equipment used in advanced pulmonary procedures. Manufacturers responded by reassessing supply chains, renegotiating sourcing agreements, and accelerating localization of critical components to mitigate exposure to trade-related cost volatility.

These adjustments reverberated downstream, influencing procurement strategies for hospital systems and integrated care networks that procure a mix of pharmacological therapies and procedural devices. Some organizations shifted toward longer term contracting and regional supplier diversification to minimize disruptions. Regulatory and customs compliance requirements also increased administrative overhead, prompting stakeholders to invest in supply chain resilience and scenario planning.

Importantly, the policy environment catalyzed conversations about domestic manufacturing capacity and strategic inventory management for high-value components. The aggregate effect was a renewed focus on manufacturing agility and risk mitigation across the product lifecycle, with commercial teams integrating tariff sensitivity into pricing, contracting, and go-to-market planning to preserve access and maintain clinical continuity for patients reliant on complex emphysema treatments.

Multidimensional segmentation insights revealing how treatment type, drug class, therapy line, and delivery channels dictate clinical adoption and commercial positioning

Key segmentation insights illuminate how therapeutic choices and commercial pathways diverge across treatment type, drug class, therapy line, route of administration, dosage form, distribution channel, and product type. Based on treatment type, the market distinguishes pharmacological options-studied across antibiotics, bronchodilators, corticosteroids, and mucolytics-from surgical approaches that include bullectomy, lung transplantation, lung volume reduction surgery, and valve therapy; this dichotomy underscores the need for coordinated care pathways that integrate medication optimization with procedural selection criteria.

When considered through the lens of drug class, anticholinergics, beta-agonists, and combination drugs dominate clinical strategies for bronchodilation and symptom control, and their evolving formulations and delivery systems directly influence adherence and clinical outcomes. Therapy line segmentation-adjunctive, first-line, maintenance, and rescue-reveals how interventions are positioned across the patient journey; within maintenance strategies, combination therapy, long-acting anticholinergics, and long-acting beta-agonists are central to sustained disease control, while rescue options rely on short-acting anticholinergics and short-acting beta-agonists to address acute symptom flares.

Route of administration is a critical commercial and clinical differentiator: inhalation modalities such as dry powder inhaler, metered dose inhaler, nebulizer, and soft mist inhaler remain primary for chronic management, whereas intravenous approaches-infusion and injection-are typically reserved for acute care or hospital-based interventions, and oral formulations including capsule, solution, and tablet provide convenience for certain therapeutic classes. Dosage form segmentation across capsule, inhaler, nebulizer, solution, and tablet aligns closely with route considerations and patient adherence profiles. Distribution channel patterns-hospital pharmacy, online pharmacy, and retail pharmacy-reflect evolving purchasing behaviors and the increasing relevance of omnichannel access to therapies. Finally, product type segmentation between brand and generic options determines pricing dynamics, formulary placement, and uptake, particularly where generics enable broader access but branded innovations support premium positioning. Collectively, these segmentation lenses offer a multidimensional view that informs product development, commercial targeting, and clinical pathway design.

How regional regulatory, reimbursement, and healthcare delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and commercialization strategies

Regional dynamics exert a strong influence on clinical practice, regulatory frameworks, and commercial strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, emphasis on integrated health systems and value-based care models has prioritized therapies and interventions that demonstrably reduce hospitalizations and improve long-term patient outcomes, prompting payers and providers to scrutinize comparative effectiveness and total cost of care. This environment fuels interest in durable maintenance regimens and device innovations that support adherence.

Within Europe, Middle East & Africa, diverse regulatory pathways and heterogeneous healthcare funding mechanisms require tailored market access plans that account for country-specific reimbursement criteria and clinical guideline adoption. Stakeholders in this region often balance innovative therapeutics with local affordability considerations, creating opportunities for differentiated access strategies that pair clinical evidence with pragmatic pricing models. Across Asia-Pacific, rapid adoption of advanced inhalation technologies and growing investment in specialist pulmonary services are expanding the addressable patient population for both pharmacological and procedural interventions; however, variations in healthcare infrastructure and reimbursement across countries necessitate flexible commercialization approaches.

These regional distinctions underscore the importance of aligning clinical development and market access activities with localized evidence generation, stakeholder engagement, and distribution strategies. Companies that tailor their evidence packages, delivery modalities, and pricing structures to regional priorities are better positioned to achieve sustainable adoption and to scale interventions across multiple healthcare contexts.

Competitive profile and strategic imperatives for companies advancing pharmacological, device-based, and procedural solutions to address multifaceted emphysema care needs

Competitive dynamics in emphysema treatment are shaped by a mix of established pharmaceutical companies, specialized device manufacturers, and emerging biotech organizations pursuing novel therapeutic modalities. Incumbent players leverage broad respiratory portfolios, deep clinician relationships, and distribution networks to maintain access across hospitals and retail channels, while emerging entrants focus on differentiated mechanisms, targeted device-drug combinations, or procedural innovation to create clinical and commercial niches. Strategic partnerships and licensing agreements remain pivotal as companies aim to combine clinical expertise with device engineering or to accelerate market entry through co-development.

R&D intensity is concentrated on improving patient outcomes through longer-acting agents, combination formulations, and inhaler technologies that reduce systemic exposure and improve adherence. On the procedural side, device refinements and improved patient selection algorithms are expanding the candidate pool for lung volume reduction and valve therapies. Corporate strategy increasingly blends lifecycle management of legacy products with targeted investment in evidence generation to support label expansion or new guideline recommendations.

M&A and alliance activity gravitates toward capability gaps-such as inhalation device platforms or digital health solutions that enable remote monitoring and adherence support. Companies that can demonstrate integrated value propositions combining clinical efficacy, improved patient experience, and logistical simplicity stand to gain traction with payers and providers. Overall, competitive success hinges on evidence-driven differentiation, agile commercialization models, and close engagement with multidisciplinary clinical teams.

Actionable strategic recommendations for industry leaders to align clinical evidence, device innovation, supply chain resilience, and regional market access execution

Industry leaders should pursue a set of actionable recommendations that align clinical differentiation with commercial pragmatism and operational resilience. First, prioritize integrated evidence generation that pairs randomized controlled trial data with real-world outcomes, emphasizing measures such as exacerbation reduction, hospitalization avoidance, and quality of life improvements to meet payer and guideline expectations. Translate these clinical data into clear value narratives that address both short-term resource impact and long-term health benefits.

Second, invest in device and formulation optimization to enhance adherence and patient experience; innovations that simplify dosing, reduce handling complexity, or improve delivery efficiency can materially affect therapeutic efficacy in routine practice. Third, strengthen supply chain resilience by diversifying suppliers, localizing critical manufacturing capabilities where feasible, and incorporating tariff sensitivity into procurement and pricing models to reduce exposure to trade disruption. Fourth, tailor market access strategies to regional realities by developing country-specific evidence packages and adaptive pricing approaches that respect local reimbursement frameworks while preserving commercial viability.

Fifth, pursue strategic partnerships that combine clinical expertise, device engineering, and digital health capabilities to create bundled solutions that resonate with multidisciplinary care teams. Finally, embed patient-centricity across development and commercial activities by leveraging patient-reported outcomes, adherence analytics, and support programs that facilitate sustained engagement. These recommendations together support robust clinical uptake and sustainable commercial performance.

An evidence-driven research methodology blending systematic literature review, clinician and executive interviews, and supply chain policy analysis to validate insights

The research methodology underpinning this analysis combined rigorous secondary intelligence with targeted qualitative engagement to ensure a comprehensive, evidence-based perspective. A systematic review of peer-reviewed clinical literature, regulatory guidance, and public health directives provided the foundational clinical and scientific context. This review was complemented by an appraisal of device approvals, procedural technique literature, and technology assessment reports to capture advancements in both pharmacological and surgical domains.

To enrich the secondary evidence base, structured interviews were conducted with clinical specialists, procurement leaders, and industry executives to surface practical insights on treatment adoption, patient selection, and operational constraints. These qualitative engagements helped validate trends observed in the literature and clarified how reimbursement and delivery models influence real-world decision-making. The methodology also included an assessment of supply chain and policy developments, focusing on how tariff adjustments and trade policy changes affect manufacturing and distribution strategies.

Data synthesis emphasized triangulation across sources to reduce bias and to highlight convergent conclusions. Limitations were acknowledged where evidence gaps persist, and recommendations were framed to be actionable within the context of identified uncertainties. This methodological approach ensures that the conclusions are grounded in multifaceted evidence and validated practitioner perspectives.

A conclusive synthesis emphasizing how clinical innovation, operational resilience, and localized market strategies will determine success in emphysema treatment

In conclusion, the emphysema treatment landscape is at an inflection point where pharmacological refinements, delivery innovations, and procedural advances converge with evolving payer expectations and regional heterogeneity. Clinical decision-making is increasingly guided by outcomes that matter to patients and health systems, and stakeholders are responding by emphasizing durable maintenance regimens, improved adherence through better devices, and precise surgical selection. These dynamics create opportunities for differentiated therapeutic strategies that combine clinical effectiveness with scalability and economic rationale.

Operationally, trade policy shifts and supply chain pressures underscore the need for manufacturers and distributors to enhance resilience and to incorporate policy sensitivity into commercial planning. Region-specific approaches will be essential, as regulatory frameworks, reimbursement models, and healthcare delivery capacities vary substantially across markets. Competitive success will favor organizations that integrate robust evidence generation, strategic partnerships, and patient-centric product design.

Moving forward, decision-makers should adopt a balanced strategy that prioritizes clinical value, operational agility, and localized market access plans. By aligning innovation with pragmatic execution, stakeholders can improve patient outcomes while navigating the complex commercial and policy landscape that frames contemporary emphysema care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of personalized inhalation devices with smart monitoring capabilities for emphysema patients
  • 5.2. Adoption of regenerative stem cell therapies targeting alveolar tissue repair in emphysema management
  • 5.3. Market adoption of next generation long acting bronchodilator combinations with enhanced safety profiles
  • 5.4. Integration of cloud connected spirometry and digital health platforms for remote emphysema monitoring
  • 5.5. Development of targeted anti inflammatory biologics to mitigate chronic alveolar degradation in emphysema
  • 5.6. Collaborations between biotech startups and pulmonary research centers to expedite emphysema drug approvals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Emphysema Treatment Market, by Treatment Type

  • 8.1. Pharmacological
    • 8.1.1. Antibiotics
    • 8.1.2. Bronchodilators
    • 8.1.3. Corticosteroids
    • 8.1.4. Mucolytics
  • 8.2. Surgical
    • 8.2.1. Bullectomy
    • 8.2.2. Lung Transplantation
    • 8.2.3. Lung Volume Reduction Surgery
    • 8.2.4. Valve Therapy

9. Emphysema Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta-Agonists
  • 9.3. Combination Drugs

10. Emphysema Treatment Market, by Therapy Line

  • 10.1. Adjunctive
  • 10.2. First-Line
  • 10.3. Maintenance
    • 10.3.1. Combination Therapy
    • 10.3.2. Long-Acting Anticholinergics
    • 10.3.3. Long-Acting Beta-Agonists
  • 10.4. Rescue
    • 10.4.1. Short-Acting Anticholinergics
    • 10.4.2. Short-Acting Beta-Agonists

11. Emphysema Treatment Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder Inhaler
    • 11.1.2. Metered Dose Inhaler
    • 11.1.3. Nebulizer
    • 11.1.4. Soft Mist Inhaler
  • 11.2. Intravenous
    • 11.2.1. Infusion
    • 11.2.2. Injection
  • 11.3. Oral
    • 11.3.1. Capsule
    • 11.3.2. Solution
    • 11.3.3. Tablet

12. Emphysema Treatment Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Inhaler
  • 12.3. Nebulizer
  • 12.4. Solution
  • 12.5. Tablet

13. Emphysema Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Emphysema Treatment Market, by Product Type

  • 14.1. Brand
  • 14.2. Generic

15. Emphysema Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Emphysema Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Emphysema Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. GlaxoSmithKline plc
    • 18.3.2. Boehringer Ingelheim International GmbH
    • 18.3.3. AstraZeneca plc
    • 18.3.4. Novartis AG
    • 18.3.5. Teva Pharmaceutical Industries Ltd
    • 18.3.6. Viatris Inc.
    • 18.3.7. Chiesi Farmaceutici S.p.A.
    • 18.3.8. Sunovion Pharmaceuticals Inc.
    • 18.3.9. Sandoz International GmbH
    • 18.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. EMPHYSEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. EMPHYSEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. EMPHYSEMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS EMPHYSEMA TRE